Safe use of non-steroidal anti-inflammatory drugs (NSAIDs) – Related resources
26.02.2016 • Sonuncu dəyişiklik 26.02.2016
This article is created and updated by the EBMG Editorial Team
Cochrane reviews
- NSAIDs cause a clinically unimportant transient reduction in renal function in early post-operative period .
- Single doses of paracetamol are effective analgesics for acute postoperative pain and give rise to few adverse effects .
- Oxycodone 10 mg plus paracetamol (acetaminophen) 650 mg provides good analgesia for acute postoperative pain in adults, comparable to commonly used non-steroidal anti-inflammatory drugs, with the benefit of longer duration of action .
- The combination of paracetamol and codeine is an effective analgesic in postoperative pain with a low incidence of adverse events .
- Coxibs are effective as single-dose treatments of postoperative pain. However, the benefits must be weighed against the possibility of adverse cardiovascular outcomes at least in some of the coxibs .
- NSAIDs are effective as single-dose treatments of postoperative pain in adults .
Other evidence summaries
- NSAIDs elevate blood pressure averagely 5 mmHg .Selective cyclooxygenase-2 inhibitors (coxibs) do not increase the risk of cerebrovascular events as compared with placebo or non-selective NSAIDs .
Celecoxib appears to produce fewer gastrointestinal adverse effects than naproxen .
Other Internet resources
- 18. EMEA/H/A-31/1344. Assessment report for diclofenac containing medicinal products (systemic formulations)
- 19. EMEA/H/A-31/1401. Ibuprofen and dexibuprofen containing medicinal products (systemic formulations)
Literature
- Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003 Jun 15;49(3):283-92.
- Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: a population-based cohort study. Am J Gastroenterol 2006 May;101(5):945-53.
- Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Bégaud B, Dequeker J, Isomäki H, Littlejohn G, Mau J, Papazoglou S. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol 1998 Sep;37(9):937-45.
- Dequeker J, Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Bégaud B, Isomäki H, Littlejohn G, Mau J, Papazoglou S. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998 Sep;37(9):946-51.